The frailty index outperforms DNA methylation age and its derivatives as an indicator of biological age by unknown
ORIGINAL ARTICLE
The frailty index outperforms DNA methylation age
and its derivatives as an indicator of biological age
Sangkyu Kim & Leann Myers & Jennifer Wyckoff &
Katie E. Cherry & S. Michal Jazwinski
Received: 18 December 2016 /Accepted: 5 January 2017 /Published online: 14 January 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract The measurement of biological age as op-
posed to chronological age is important to allow the
study of factors that are responsible for the heteroge-
neity in the decline in health and function ability
among individuals during aging. Various measures
of biological aging have been proposed. Frailty indi-
ces based on health deficits in diverse body systems
have been well studied, and we have documented the
use of a frailty index (FI34) composed of 34 health
items, for measuring biological age. A different ap-
proach is based on leukocyte DNA methylation. It
has been termed DNA methylation age, and deriva-
tives of this metric called age acceleration difference
and age acceleration residual have also been
employed. Any useful measure of biological age
must predict survival better than chronological age
does. Meta-analyses indicate that age acceleration
difference and age acceleration residual are signifi-
cant predictors of mortality, qualifying them as indi-
cators of biological age. In this article, we compared
the measures based on DNA methylation with FI34.
Using a well-studied cohort, we assessed the efficien-
cy of these measures side by side in predicting mor-
tality. In the presence of chronological age as a co-
variate, FI34 was a significant predictor of mortality,
whereas none of the DNA methylation age-based
metrics were. The outperformance of FI34 over
DNA methylation age measures was apparent when
FI34 and each of the DNA methylation age measures
were used together as explanatory variables, along
with chronological age: FI34 remained significant but
the DNA methylation measures did not. These results
indicate that FI34 is a robust predictor of biological
age, while these DNA methylation measures are
largely a statistical reflection of the passage of chro-
nological time.
Keywords Aging . Biological age . Frailty . DNA
methylation .Mortality
Introduction
Degenerative biological changes and functional de-
cline occur with advancing age, increasing the inci-
dence of disorders, diseases, and mortality. Thus,
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biological aging proceeds in tandem with chrono-
logical age. However, the pace and extent of age
changes vary among individuals at any given chro-
nological age (Mitnitski et al. 2002a; Karasik et al.
2005). Thus, the term biological aging has been
developed to conceptualize the fact that individuals
differ in their manifestation of age changes as they
age chronologically. The heterogeneity in biological
aging among chronological age peers necessitates a
reliable measure of biological or functional age sep-
arate from chronological age.
A good measure of biological age should reflect
age-related changes occurring at various biological
levels. One of the best characterized measures of
biological age is the frailty (or deficit) index
(Rockwood et al. 1994, 1999; Fried et al. 2001;
Mitnitski et al. 2001; Kulminski et al. 2007a, b).
This composite index is expressed as the proportion
of health deficits accumulated by individuals among
a set of health items surveyed throughout the body,
and it can be calculated at any given chronological
age (Mitnitski et al. 2001). The health items
(variables) include various signs, symptoms, labora-
tory measurements, disabilities, and diseases. A
frailty index calculated from about 20 to 100 health
variables gives reliable and comparable results
(Mitnitski et al. 2006; Rockwood et al. 2007;
Rockwood and Mitnitski 2007; Searle et al. 2008).
Frailty indexes have been extensively examined and
used in various studies (Mitnitski et al. 2001, 2002a,
b; Kulminski et al. 2007a, b; Matteini et al. 2010).
We developed a frailty index called FI34 (Kim
et al. 2013; Kim and Jazwinski 2015). Composed
of 34 common health and function variables, FI34
increases exponentially with age, indicating declin-
ing health and function ability. The rate of increase
accelerates approximately 2~3 % annually, and the
rate of increase and the pattern of aging displayed
by the hierarchical clustering of the component var-
iables differ among offspring of long-lived versus
short-lived parents (Kim et al. 2013), which indi-
cates a genetic basis of the frailty index. Indeed, an
estimate of the heritability (narrow sense) of FI34 is
relatively high (0.39). A survival analysis indicates
that FI34 predicts mortality better than does chrono-
logical age (Kim et al. 2013). This is a critical
determination. Frailty and deficit indices, such as
FI34, increase with chronological age. Thus, they
could simply be a surrogate for the passage of cal-
endar time. The fact that FI34 predicts mortality/
survival better than does the simple passage of time
indicates that it is more than a naive chronometer.
Rather, it is a metric of biological age, a complex
and intrinsic feature of an organism.
Physiologic factors associated with FI34 have
been identified. Elevated levels of resting metabolic
rate are linked to higher FI34 scores in nonagenar-
ians, indicating an increased energy demand for
basic body functioning with declining health (Kim
et al. 2014). This association of energy metabolism
with healthy aging of the oldest old has various
underlying factors that operate in a gender-specific
manner (Kim et al. 2016a, b). In female nonagenar-
ians, fat mass and fat-free mass are important con-
tributors to healthy aging; in male nonagenarians,
however, tissue quality rather than body composi-
tion is important. In addition, genetic factors that are
associated with FI34 have been identified, which
include UCP2 and UCP3, in females, and XRCC6,
and LASS1, in males. Also, non-coding genomic
regions at 12q13-14 that appear to have regulatory
function are related to healthy aging (Kim et al.
2015). Thus, FI34 has been useful in identifying both
genetic and phenotypic factors related to healthy
aging.
A different type of age measure was proposed
based on leukocyte DNA methylation. DNA methyl-
ation levels at many CpG sites in the genome are
correlated with chronological age (Fraga et al. 2005;
Rakyan et al. 2010; Bocklandt et al. 2011; Koch and
Wagner 2011; Lin et al. 2016), and subsets of such
CpG sites have been used in epigenetic models of
aging. Hannum et al. obtained a Bpredicted age^ from
DNA methylation levels at 71 CpG sites and calcu-
lated an Bapparent methylomic aging rate (AMAR)^
for each individual by dividing the predicted age by
the chronological age (Hannum et al. 2013). AMAR
greater than 1 was interpreted to mean Bfast aging,^
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whereas AMAR less than 1 to mean Bslow aging.^
Similarly, Horvath selected 353 CpG sites in which
DNA methylation levels are highly correlated with
chronological age (Horvath 2013). He transformed
subjects’ chronological ages (1 and 2 below), used a
linear regression to describe the relationship between
the transformed age and the DNA methylation levels
of the 353 CpG sites that are highly correlated with
chronological age Bweighted^ by their regression
coefficients to maximize the overall relationship (3),
and then took the Binverse^ of this linear regression
to calculate the DNAmAge of each subject (4):
F ageð Þ ¼ log ageþ 1ð Þ− log adult ageþ 1ð Þ; i f age ≤ adult age ¼ 20ð Þ ð1Þ
F ageð Þ ¼ age−adult ageð Þ= adult ageþ 1ð Þ; i f age> adult age ¼ 20ð Þ
F ageð Þ ¼ b0 þ b1CpG1 þ b2CpG2…b353CpG353 þ error
DNAmAge¼ the “inverse” of the function F in 3ð Þ ð4Þ
Not surprisingly based on its dependence on chrono-
logical age, the DNAmAge is an excellent correlate of
chronological age. Indeed, it is almost as accurate as the
age on drivers’ licenses. Subsequently, the potential of
DNAmAge-derivedmeasures as indicators of biological
age have been explored (Horvath et al. 2015; Marioni
et al. 2015; Breitling et al. 2016; Chen et al. 2016;
Christiansen et al. 2016; Perna et al. 2016). One of them,
AgeAccelerationDiff (AgeDiff hereafter), is the differ-
ence between DNAmAge and chronological age.
AgeDiff was associated with mortality (Marioni et al.
2015; Christiansen et al. 2016; Perna et al. 2016). It was
also associated with a frailty index similar to our FI34
but having a much greater emphasis on activities of
daily living and a substantially lesser focus on cognitive
function (Breitling et al. 2016). Likewise, the residual of
the linear regression of DNAmAge on chronological
age, AgeAccelerationResidual (AgeResid hereafter),
was associated with longevity and mortality (Horvath
et al. 2015; Chen et al. 2016). These findings indicate
that these DNAmAge-derived measures may represent
biological age.
In this article, we compared DNAmAge measures
with FI34 side by side and assessed the effectiveness of
each of these measures in predicting mortality. Our
results indicate that FI34 uniformly outperforms the
DNAmAge measures.
Materials and methods
Subjects and health data
Subjects in this study are 262 unrelated individuals
randomly selected from the Louisiana Healthy Aging
Study cohort (Table 1). Age was based on documentary
evidence supported by demographic questionnaires.
Only Caucasians, inferred genetically, were included in
data analyses to avoid population confounding
(Jazwinski et al. 2010). Details of data collection and
calculation and characterization of FI34 were described
elsewhere (Kim et al. 2013). All participants provided
informed consent according to the protocol approved by
the respective Institutional Review Boards.
DNA methylation data and analysis
Genomic DNAwas isolated from blood specimens, and
500 ng of each genomic DNA sample was treated with
bisulfite using the EZ-96 DNA methylation Kit (Zymo
Research). DNA methylation data were obtained using
the Infinium HumanMethylation450K BeadChip Kit
(Illumina) at the University of Utah Genomics Core
Facility. Data preprocessing and quality control were
done using the R package RnBeads (Assenov et al.
(2)
(3)
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2014). DNA methylation probes with the detection P
value greater 0.05 were excluded from beta value cal-
culation. DNA methylation age (BDNAmAge^) of each
subject was obtained using the Online Age Calculator
(https://dnamage.genetics.ucla.edu/) (Horvath 2013),
with the recommended default setting. The DNAmAge
was calculated directly without retraining the model on
the DNAmethylation data from our study population, as
the online calculator was developed using a large col-
lection of genome-wide methylation datasets. The out-
put from the online calculator also contains cell count
estimates of various leukocyte types, which were used
as additional covariates in Cox proportional hazard re-
gression analysis. All the statistical analyses were per-
formed using R (R_Core_Team 2016).
Results
Characteristics of the study cohort
Our study sample consists of 262 Caucasians whose
ages range from 60 to 103 (Table 1). Of these, 206
(79 %) were deceased at the time of follow-up just prior
to this analysis, and the average elapsed time-to-death
from entry into the study was 4.4 years. Females and
males did not differ in mean chronological ages and
mean DNAmAges, but the two gender groups signifi-
cantly differed in FI34, AgeDiff, and AgeResid. FI34 was
higher in females (P = 5.2e-5), as described previously
(Kim and Jazwinski 2015). On the other hand, AgeDiff
and AgeResid were higher in males (P = 0.0025 and
0.0086, respectively), which concurs with the higher
AMAR in males (Hannum et al. 2013).
DNAmAge and FI34 are correlated with age
DNAmAge is derived from transformed chronological
age in a statistical model in which the chronological age
is regressed on the methylation status of 353 CpG sites
throughout the genome (Horvath 2013). Thus,
DNAmAge is expected to be highly correlated with
chronological age. For example, the average correlation
coefficients were 0.97 and 0.96 for all training and test
data sets, respectively (Horvath 2013). Likewise, in our
sample, DNAmAge was significantly correlated with
chronological age (r = 0.63, P < 2.0e-16; Fig. 1a). FI34
was also correlated linearly with chronological age as
health and function deficits tend to increase with age
(r = 0.31, P = 4.4e-7; Fig. 1b), although an exponential
model describes the relationship better (Kim et al. 2013;
Kim and Jazwinski 2015). AgeDiff was also correlated
with chronological age (r = −0.20, P = 9.3e-4; Fig. 1c),
while AgeResid was not (Fig. 1d).
Table 1 Summary statistics of the study sample (N = 262; 206 deceased)
Measure Group Range Mean ± SD Male vs. femalea
Age All (262) 60∼103 86 ± 10 P = 0.28
Male (103) 60∼99 85 ± 11
Female (159) 60∼103 87 ± 9
FI34 All 0.0097∼0.49 0.22 ± 0.092 P = 5.2e-5
Male 0.0097∼0.45 0.19 ± 0.085
Female 0.032∼0.49 0.23 ± 0.091
DNAmAge All 32∼110 78 ± 12 P = 0.45
Male 43∼110 78 ± 13
Female 32∼107 78 ± 12
AgeDiff All −41∼29 −8 ± 10 P = 0.0025
Male −41∼19 −6 ± 10
Female −41∼29 −9 ± 10
AgeResid All −36∼36 0 ± 10 P = 0.0086
Male −31∼28 1.8 ± 10
Female −36∼36 −1.2 ± 9
SD standard deviation
aWilcoxon rank sum tests between the two gender groups
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As both FI34 and DNAmAge were correlated with
chronological age, FI34 and DNAmAge were correlated
with each other (r = 0.20, P = 0.0013; Fig. 2a). How-
ever, the correlation disappeared when adjusted for
chronological age (P > 0.5 by partial correlation), indi-
cating that without the age dependence, DNAmAge,
and FI34 are unrelated. AgeDiff and AgeResid were
not correlated with FI34 (Fig. 2b, c).
DNAmAge is not a significant predictor of survival
when adjusted for age
The performance of a measure of biological age is best
assessed by its ability to predict mortality, which is the
ultimate consequence of aging. For this purpose, most of
the studies of DNAmAgemeasures used Cox proportion-
al hazard regression. We applied the same statistical
method to our survival data (Table 2). As expected,
chronological age was a significant predictor of survival:
The hazard of death was estimated to increase 13 %
annually (P < 2.0e-16; model 1). DNAmAge increased
the hazard of death by 5 % for a unit increase in
DNAmAge (P = 3.3e-16; model 2). Likewise, FI34 was
estimated to increase the mortality hazard by 5 % for an
increase of FI34 by 0.01 (P = 4.8e-10; model 3). When
present together as explanatory variables, DNAmAge
and FI34 remained significant without affecting each other
much (P = 2.6e-13 and 8.2e-7, respectively; model 4). In
the presence of chronological age as an additional covar-
iate, however, DNAmAge was no longer a significant
mortality predictor (P = 0.63 and 0.61 in models 5 and 7,
respectively), while FI34 still remained significant
(P = 0.0054 and 0.0053 in models 6 and 7, respectively).
These results confirm that DNAmAge and chronological
age largely overlap with each other, but FI34 is a separate
measure distinct from the two.
Different types of leukocytes exist in blood, and their
proportions may vary, depending on individuals’ health
conditions at the time of blood collection. This leukocyte
heterogeneity may confound estimation of intrinsic DNA
a c
b d
Fig. 1 Scatter plots of
chronological age (Age) by
DNAmAge (a), FI34 (b), AgeDiff
(c), and AgeResid (d). Each re-
gression line is from the corre-
sponding standardized simple
linear regression, whose β value
equals the correlation coefficient r
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methylation levels (Reinius et al. 2012). Methods to esti-
mate leukocyte type counts were developed and have
been often used to adjust DNAmethylationmeasurements
(Houseman et al. 2012, 2014; Accomando et al. 2014).
Therefore, leukocyte type estimates were obtained using
Horvath’s Online Age Calculator and included as addi-
tional covariates in our Cox regression analysis. The
outcome of the leukocyte composition adjustment (model
8) was very similar to the outcome without the adjustment
(model 7). The only noticeable difference is a slight
decrease in the Z value of FI34 from 2.8 to 2.4, resulting
in a higher P value (P from 0.0053 to 0.016). This small
change is likely due to the redundancy of FI34 and leuko-
cyte composition in reflecting health conditions.
The Cox regression analysis was repeated with
AgeDiff (Table 3). A unit increase in AgeDiff was
estimated to reduce the hazard by 2 % (P < 0.020;
model 1). When present together, AgeDiff and FI34
remained significant without affecting each other
much (P = 0.028 and 6.1e-10, respectively; model
2). Along with chronological age, however, AgeDiff
was not significant at all, whereas FI34 maintained its
significance (models 3–5). The Cox regression analy-
sis was also repeated with AgeResid (Table 4), but
AgeResid was not significant under any of the covar-
iate combinations. As before, FI34 remained signifi-
cant in all the models considered in Table 4.
FI34 outperforms chronological age
and DNAmAge-related measures in predicting
mortality of nonagenarians
In all the Cox regression models presented so far with
the whole study cohort, which includes subjects of ages
from 60 to 103, chronological age was the best predictor
of mortality (Fig. 3a). When the Cox regression was
limited to nonagenarians only, however, FI34 was a
better predictor of mortality than chronological age
(P = 0.035 vs. P = 0.054, respectively; Fig. 3b). This
indicates that FI34 is a better measure of biological age at
later years when accumulation of health deficits accel-
erates differentially among the oldest old.
a
b
cFig. 2 Scatter plots of FI34 by
DNAmAge (a), AgeDiff (b), and
AgeResid (c). Each regression
line is from the corresponding
standardized simple linear
regression, whose β value equals
the correlation coefficient r
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Discussion
Since Horvath’s calculation of DNAmAge based on
genomic DNA methylation levels (beta values) and
chronological age (Horvath 2013), two DNAmAge-
derived measures have been used: AgeDiff and
AgeResid. AgeDiff has been associated with mortality
(Marioni et al. 2015; Christiansen et al. 2016; Perna
Table 2 Cox regression for time-to-death as a function of age, DNAmAge, or FI34 (N = 262)
Model Variables b exp(b) se(b) Z P R2 Wald test P
1 Age 0.12 1.13 0.011 11 <2.0e-16 0.48 <2.0e-16
2 DNAmAge 0.048 1.05 0.0059 8.2 3.3e-16 0.22 3.0e-15
3 FI34
a 0.049 1.05 0.0079 6.2 4.8e-10 0.13 2.6e-09
4 DNAmAge 0.046 1.05 0.0063 7.3 2.6e-13 0.29 <2.0e-16
FI34
a 0.039 1.04 0.0079 4.9 8.2e-07
5 Age 0.12 1.12 0.012 9.4 <2.0e-16 0.48 <2.0e-16
DNAmAge 0.0037 1.00 0.0077 0.49 0.63
6 Age 0.11 1.12 0.011 10 <2.0e-16 0.49 <2.0e-16
FI34
a 0.022 1.02 0.0080 2.8 0.0054
7 Age 0.11 1.12 0.012 8.8 <2.0e-16 0.50 <2.0e-16
DNAmAge 0.0050 1.00 0.0078 0.52 0.61
FI34
a 0.022 1.02 0.0080 2.8 0.0053
8 Age 0.11 1.12 0.013 8.6 <2.0e-16 0.51 <2.0e-16
DNAmAge 0.0039 1.00 0.0084 0.47 0.64
FI34
a 0.020 1.02 0.0085 2.4 0.016
WBCb – – – –
All the regressions above contained sex as a covariate
b regression coefficient, exp(b) exponentiated b, se(b) standard error of b, Z the ratio of b to its standard error
a FI34 was multiplied by 100; therefore, the b value for FI34 is the hazard of death for an increase of FI34 by 0.01
b CD8.naive + CD8pCD28nCD45Ran + PlasmaBlast + CD4T + NK + Mono + Gran
Table 3 Cox regression for time-to-death as a function of AgeDiff or FI34 (N = 262)
Model Variables b exp(b) se(b) Z P R2 Wald test P
1 AgeDiffc −0.017 0.98 0.0074 −2.3 0.020 0.022 0.053
2 AgeDiffc −0.017 0.98 0.0075 −2.2 0.028 0.15 1.7e-09
FI34
a 0.049 1.05 0.0079 6.2 6.1e-10
3 Age 0.12 1.13 0.011 11 <2.0e-16 0.48 <2.0e-16
AgeDiffc 0.0037 1.00 0.0077 0.49 0.63
4 Age 0.11 1.12 0.011 10 <2.0e-16 0.49 <2.0e-16
AgeDiffc 0.0040 1.00 0.0078 0.52 0.61
FI34
a 0.022 1.02 0.0080 2.8 0.0053
5 Age 0.11 1.12 0.012 10 <2.0e-16 0.51 <2.0e-16
AgeDiffc 0.0039 1.00 0.0084 0.47 0.64
FI34
a 0.020 1.02 0.0085 2.4 0.016
WBCb – – – –
All the regressions above contained sex as a covariate
b regression coefficient, exp(b) exponentiated b, se(b) standard error of b, Z the ratio of b to its standard error
a FI34 was multiplied by 100; therefore, the b value for FI34 is the hazard of death for an increase of FI34 by 0.01
b CD8.naive + CD8pCD28nCD45Ran + PlasmaBlast + CD4T + NK + Mono + Gran
cAgeDiff = AgeAccelerationDiff = DNAmAge − chronological age
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et al. 2016) and a frailty index (Breitling et al. 2016),
after adjustment for various sets of covariates, including
the leukocyte type composition. More recently, Chen
et al. expanded the original observation of Horvath
using more than 13,000 individuals from 13 different
cohorts, including three racial/ethnic groups, and found
AgeResid to be a significant predictor of mortality
(Horvath 2013; Chen et al. 2016). They also found that
incorporation of leukocyte composition information
greatly enhanced the significance of AgeResid in
predicting mortality.
A true measure of biological age should predict
mortality/survival with high accuracy. Our study
showed that FI34 is a significant predictor of mortality,
Table 4 Cox regression for time-to-death as a function of AgeResid or FI34 (N = 262)
Model Variables b exp(b) se(b) Z P R2 Wald test P
1 AgeResidc 0.0023 1.00 0.0079 0.29 0.77 0.002 0.74
2 AgeResidc 0.00062 1.00 0.0081 0.076 0.94 0.13 1.3e-08
FI34
a 0.049 1.05 0.0079 6.2 5.2e-10
3 Age 0.12 1.13 0.011 11 <2.0e-16 0.48 <2.0e-16
AgeResidc 0.0037 1.00 0.0077 0.49 0.63
4 Age 0.11 1.12 0.011 10 <2.0e-16 0.49 <2.0e-16
AgeResidc 0.0040 1.00 0.0078 0.52 0.61
FI34
a 0.022 1.02 0.0080 2.8 0.0053
5 Age 0.11 1.12 0.012 9.8 <2.0e-16 0.51 <2.0e-16
AgeResidc 0.0039 1.00 0.0084 0.47 0.64
FI34
a 0.020 1.02 0.0085 2.4 0.016
WBCb – – – –
All the regressions above contained sex as a covariate
b regression coefficient, exp(b) exponentiated b, se(b) standard error of b, Z the ratio of b to its standard error
a FI34 was multiplied by 100; therefore, the b value for FI34 is the hazard of death for an increase of FI34 by 0.01
b CD8.naive + CD8pCD28nCD45Ran + PlasmaBlast + CD4T + NK + Mono + Gran
c Residual = y − ŷ in linear regression of ŷ (DNAmAge) on y (chronological age)
Fig. 3 Bar plots of effect sizes (Z
scores) from Cox proportional
hazards regressions. a Z scores in
model 7 of Table 2, model 4 of
Table 3, and model 4 of Table 4
were plotted, with * representing
0.01 < P =< 0.05, ** 0.001
< P =< 0.01, and P =< 0.001.
b Z scores from the same Cox
regression models applied to
nonagenarians only (N = 161)
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whereas DNAmAge, AgeDiff, and AgeResid are not,
regardless of adjustment for leukocyte type composi-
tion. Our study sample consists of 262 Caucasians
whose ages range from 60 to 103, and by comparing
FI34 and each of the DNAmAge measures side by side,
we clearly showed that FI34 is a far better predictor of
mortality than the DNAmAge measures. DNAmAge
was significant when the Cox regression was unadjusted
for chronological age, but DNAmAge became nonsig-
nificant when the regression was adjusted for this vari-
able. This confirms a high degree of redundancy be-
tween DNAmAge and chronological age. The same is
true with AgeDiff, the difference between DNAmAge
and chronological age. Because DNAmAge and age are
highly correlated with each other, AgeDiff is also cor-
related with age, though the correlation is not as strong
as that of DNAmAge with chronological age. The neg-
ative correlation of AgeDiff with chronological age
(Fig. 1c) indicates that the difference between
DNAmAge and chronological age decreases as chrono-
logical age increases, which is due to decreasing
DNAmAge with increasing chronological age. A simi-
lar observation was made in a longitudinal twin study
(Christiansen et al. 2016). The cause of this leveling of
DNAmAge relative to chronological age in later years
of life remains to be determined. On the other hand,
AgeResid, the residual of the linear regression of
DNAmAge on chronological age, is not correlated with
chronological age or DNAmAge. This is not surprising
because residuals from linear regressions are not corre-
lated with either of the variables used to calculate them.
However, AgeResid was not a significant predictor of
mortality in all the models we examined in our study. A
larger sample size would likely give better linear regres-
sion fitting, which would yield better residual estimates.
This could be one reason why our study could not detect
a significance association of AgeResid with survival.
Our study used a cohort consisting of 262 subjects of
European origin, whereas all the studies of DNAmAge
used meta-analyses of the results from multiple cohorts
involving many more subjects. A meta-analysis of com-
binable studies, if based on accurate statistical procedures
without any bias, should give a higher statistical power
than individual studies. Thus, it is possible that the meta-
analysis studies involving large numbers of subjects were
able to detect the significance of the various DNAmAge
measures that our study was unable to. However, this
consideration points to the fact that FI34 is a much more
robust predictor of survival and measure of biological age
than any of the DNAmAge measures proposed thus far.
This is because it assesses biological factors that have
large effects on survival, whereas the DNAmAge mea-
sures only detect small statistical differenceswhich require
very large samples. It is worth noting that this usually
involves the use of leukocyte type estimates, which per-
haps introduce some biological meaning that is sufficient
to make them perform. FI34 is a particularly strong mea-
sure of biological age because it is a better predictor of
survival than is chronological age (Fig. 3) in the oldest old.
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